Important Safety Information and Indication
  • BeneFix, Coagulation Factor IX (Recombinant), is contraindicated in patients who have manifested life-threatening, immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster protein.
  • Hypersensitivity reactions, including anaphylaxis, have been reported with BeneFix. Closely monitor patients for signs and symptoms of acute anaphylaxis, particularly during the early phases of initial exposure to the product. Immediately discontinue the administration of the product and initiate appropriate treatment if symptoms occur.
  • Patients may develop hypersensitivity to hamster (CHO) protein as BeneFix contains trace amounts.
  • BeneFix has been associated with the development of thromboembolic complications, including patients receiving continuous infusion through a central venous catheter. The safety and efficacy of BeneFix administration by continuous infusion have not been established.
  • Neutralizing antibodies (inhibitors) have been reported following the administration of BeneFix. If expected plasma factor IX activity levels are not attained, or if the patient presents with an allergic reaction, or if bleeding is not controlled following an expected dose of BeneFix, perform an assay that measures factor IX inhibitor concentration.
  • The most common adverse reactions (>5%) from clinical trials were nausea, injection site reaction, injection site pain, headache, dizziness and rash.


BeneFix, Coagulation Factor IX (Recombinant), is a human blood coagulation factor indicated in adult and pediatric patients with hemophilia B (congenital factor IX deficiency or Christmas disease) for the control and prevention of bleeding episodes and peri-operative management.

Limitations of use:

BeneFix is NOT indicated for:

  • treatment of other factor deficiencies (eg, factors II, VII, VIII and X),
  • treatment of hemophilia A patients with inhibitors to factor VIII,
  • reversal of coumarin-induced anticoagulation,
  • treatment of bleeding due to low levels of liver-dependent coagulation factors.

Please see Full Prescribing Information for BeneFix

Trial Prescription Program

Trial Prescription Program—Start your eligible patients on BeneFix

Trial Prescription Program allows your patient to get a one-time, 1-month supply up to 20,000 IU of Pfizer factor product delivered at no cost to him or her.

Trial Prescription Program

For first-time use by commercially insured patients only.

Getting started: How to enroll

1. Determine if your patient is eligible.

Your patient must be currently covered by a private (commercial) insurance plan. If your patient is not eligible for the Trial Prescription Program, you may find help accessing Pfizer factor medicines by contacting the Pfizer RxPathways® program at 1.877.744.5675

2. Download and complete the enrollment and authorization forms.

Direct your patient to download the appropriate forms. Your patient may also contact his or her local Pfizer Hemophilia representative, or try our hotline number 1.888.999.2349. To enroll, your eligible patient must read the terms and conditions and complete parts 1–4 of the form; parts 5–13 are to be completed by the physician.

3. Write a prescription and submit the forms.

Depending on which medication you prescribe your patient, fax the completed form with the prescription and the patient authorization form to 1.888.868.8660. Fax must be sent from a health care provider’s office. You may also mail required documents to:

Trial Prescription Program Administrator, MedVantx
PO Box 5736
Sioux Falls, SD 57117-5736

Please allow 1 to 3 weeks after submission of forms for processing and delivery.

If your patient requires more assistance, the Pfizer RxPathways® program may be able to help. For more information, please see the Pfizer RxPathways page.

For questions about the Factor Product Trial Prescription Program, please call 1.800.710.1379, Monday through Friday, 9:00 AM – 5:00 PM ET or visit our resources and support page on for more information.

Download a compressive guide on financial support from Pfizer Hemophilia.

OFFER TERMS: By enrolling in the Pfizer Factor Product Trial Prescription Program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

You are currently covered by a private [commercial] insurance plan. An original free trial offer and a valid prescription must be presented. No claim for reimbursement for Pfizer factor products dispensed pursuant to this free trial offer may be submitted to any third-party payor. Medicaid, Medicare, or any other federal or state health care program beneficiaries are not eligible for this offer (this includes any state prescription drug assistance programs and the Government Health Insurance Plan, available in Puerto Rico, formerly known as “La Reforma de Salud”). The free trial offer is not valid for prescriptions that are eligible to be reimbursed by private insurance plans or health or pharmacy benefit programs that reimburse you for the entire cost of your prescription drugs. This free trial offer is not valid where otherwise prohibited by law. You will receive a 1-month supply up to 20,000 IU of factor. The free trial offer cannot be combined with any other rebate/coupon, free trial, or similar offer for the prescribed prescription. The free trial offer will only be accepted by participating factor providers. This free trial offer is not health insurance. Offer good only in the U.S. and Puerto Rico. Only new patients may use this offer. By redeeming this offer, you certify that you are not currently using Pfizer factor products. Only 1 offer per person may be redeemed under this program. This offer is not transferable. Pfizer reserves the right to rescind, revoke, or amend this free trial offer without notice. Offer expires 1 month from enrollment date or when the maximum benefit up to 20,000 IU at no cost has been reached. No membership fees.

Pfizer RxPathways is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation.

*BeneFix was approved February 11, 1997.1

Terms and conditions apply.